Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 11Thyroid Carcinoma, Anaplastic 9Thyroid Cancer, Papillary 4Neoplasms 3Multiple Myeloma 3Glioma 3Ovarian Neoplasms 2Melanoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma, Follicular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Stomach Neoplasms 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Lymphoproliferative Disorders 1Lymphoma 1Lung Neoplasms 1

Interventions

trametinib 1lenvatinib 1dabrafenib 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × dabrafenib × Head & Neck × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡